Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug resistance in mutant FLT3-positive AML.

Oncogene - 16 Sept 2010

Weisberg E, Sattler M, Ray A, Griffin J D

Abstract excerpt

Mutant Fms-Like Tyrosine kinase-3 (FLT3), which is expressed in the leukemic cells of a subpopulation of acute myeloid leukemia (AML) patients, represents an attractive target for the therapy of AML. There are several FLT3 inhibitors presently in clinical trials with sufficient efficacy and toxicity features to warrant further testing in combination with standard therapies. However, the transient and partial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to FLT3 gene

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Signal Transduction

Source

Identifiers

PMID: 20622902
DOI: 10.1038/onc.2010.273

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug resistance in mutant FLT3-positive AML.PMID 20622902Read ↗

Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.Semantic proximity Read ↗

FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance.Semantic proximity Read ↗

FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review.Semantic proximity Read ↗

Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategiesSemantic proximity Read ↗

FLT3 as a therapeutic target in AML: still challenging after all these yearsSemantic proximity Read ↗

Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemiaSemantic proximity Read ↗

Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy.Semantic proximity Read ↗

Can FLT3 inhibitors overcome resistance in AML?Semantic proximity Read ↗

FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.Semantic proximity Read ↗

The role of FLT3 kinase as an AML therapy target.Semantic proximity Read ↗

FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects.Semantic proximity Read ↗

Targeting FLT3 mutations in AML: review of current knowledge and evidenceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.